- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04415892
The Role of TRP Channels in CIPN
The Role of Transient Receptor Potential Channels in Chemotherapy-Induced Peripheral Neuropathic Pain.
Part I:
Evaluating the increase in dermal blood flow upon topical application of cinnamaldehyde and capsaicin on the fingers in healthy, male volunteers. In addition, the inter-period and inter-hand reproducibility of the increase in dermal blood flow will be assessed.
Part II:
Evaluating the increase in dermal blood flow upon topical application of cinnamaldehyde and capsaicin on the fingers in patients suffering from chemotherapy-induced peripheral neuropathy compared to matched healthy volunteers.
Part III:
Evaluating the increase in dermal blood flow upon topical application of cinnamaldehyde and capsaicin on the fingers in patients who are treated with paclitaxel or oxaliplatin.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary aim is to investigate whether paclitaxel and/or oxaliplatin alter TRP channel functionality in vivo in human. TRP functionality can indirectly be assessed via dermal blood flow changes which are part of the so-called neurogenic inflammation, induced upon TRP activation. In vivo in human, TRP can be activated via topical application of cinnamaldehyde or capsaicin on the skin.
In Part I of the study, the DBF changes upon topical application of cinnamaldehyde or capsaicin on the fingers will be characterized, including inter-period and inter-hand reproducibility.
In Part II, patients who are suffering from chronic CIPN after treatment with paclitaxel or oxaliplatin are included. DBF changes upon cinnamaldehyde and capsaicin are compared to a matched control group.
In Part III, DBF changes are assessed in patients prior to the first administration of taxol/oxaliplatin and at regular points in time during the dosage regimen.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Heleen Marynissen, MD
- Phone Number: +3216347014
- Email: heleen.marynissen@uzleuven.be
Study Locations
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgium, 3000
- Recruiting
- KU Leuven
-
Contact:
- Heleen Marynissen
- Phone Number: +3216342201
- Email: heleen.marynissen@uzleuven.be
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria Healthy volunteers:
- Subject is a white male ≥18 and ≤45 years of age.
- Subject is a non-smoker for at least 6 months prior to the start of the study.
- Subject has a body mass index between 18-30 kg/m².
- Subject is judged to be in good health on the basis of medical history, physical examination and vital signs.
- Subject understands the procedures and agrees to participate in the study by giving written informed consent.
- Subject is matched to the patient groups for sex, age and BMI (only part II).
Inclusion Criteria Patients of Part II:
- Subject is a white male or female ≥18 and ≤70 years of age.
- Subject is a non-smoker for at least 6 months prior to the start of the study.
- Subject has a BMI between 18-35 kg/m².
Subject has a history of treatment with one of the following chemotherapeutic agents:
- Paclitaxel
- Oxaliplatin
- Subject suffers from peripheral neuropathy grade 1, 2 or 3 according to the Total Neuropathy Score (clinical version). Grade 1 correlates to a score of 1-7, grade 2 to a score of 8-14 and grade 3 to a score of 15-21(10-12).
- Subject suffers from neuropathic symptoms in the upper limbs.
- Discontinuation or termination of therapy with the chemotherapeutic agent occurred >1 month and < 1 year ago.
- Subject understands the procedures and agrees to participate in the study by giving written informed consent.
Inclusion Criteria for patients of Part III
- Subject is a white male or female ≥18 and ≤75 years of age.
- Subject is a non-smoker for at least 6 months prior to the start of the study.
- Subject has a BMI between 18-35 kg/m².
- Subject will receive treatment with paclitaxel or oxaliplatin in the near future.
- Subject understands the procedures and agrees to participate in the study by giving written informed consent.
Exclusion Criteria:
- Subject has eczema, scleroderma, psoriasis, dermatitis, or keloids, tumors, ulcers, burns, flaps or grafts on their fingers or any other abnormality of the skin which, in the opinion of the investigator may interfere with the study assessments.
- Subject has excessive hair growth on the fingers.
- Subject cannot avoid excessive tanning (any exposure to sunlight or a tanning bed which would cause a sunburn reaction) throughout the study.
- Subject has a history of significant severe (drug) allergies.
- Subject uses any prescription or non-prescription drugs on a regular basis which, in the investigator's opinion, might confound the results of the study.
- Subject currently uses lotions, oils, depilatory preparations, makeup, or other topical treatments on the fingers on a regular basis which cannot be discontinued for the duration of the study.
- Subject is unable to refrain from drinking alcohol 24 hours prior to each study visit, is currently a regular user of any illicit drugs, or has a history of drug (including alcohol) abuse.
- Subject is unable to refrain from drinking caffeinated beverages (e.g. coffee, tea, cola, …) 24 hours prior to each study visit. Subject is unable to limit their intake of caffeinated beverages to ≤4 cups a day throughout the study.
- Subject has any of the following vital sign measurements at screening after at least 10 minutes of supine rest: Heart Rate <40 or >100 beats/min, Diastolic Blood Pressure <50 or >90 mmHg, Systolic Blood Pressure <90 or >140 mmHg.
- Subject is currently participating or has been involved in testing an investigational drug in another clinical study within the last 4 weeks.
- Subject is in a situation or has a condition which, in the opinion of the investigator, may interfere with safe and optimal participation in the study.
- Subject has a history of any illness or disorder which, in the investigator's opinion, might confound the results of the study.
- Subject suffered from peripheral neuropathy prior to the chemotherapeutic treatment (Only for patients).
- Subject has (a history of) diabetes mellitus, amyloidosis, vitamin B deficiency or any other medical disorder that, in the investigator's opinion, may cause peripheral neuropathy (only for Part II and III).
- Subject has (a history of) a lesion in the central nervous system that is known to possibly cause neuropathic pain: e.g. spinal cord injury, infarction localized in the brainstem or thalamus, syringomyelia, multiple sclerosis, or any other disorder of the CNS that, in the investigator's opinion, may cause neuropathic pain (only for Part II and III).
- Subject has a history of treatment with bortezomib, vincristine, or any other compound that, in the investigator's opinion, may cause neuropathic pain (only for Part II and III).
- Subject did not develop neuropathy after treatment with epirubicine-cyclofosfamide (only for the paclitaxel group in Part III).
- Subject has a family history of peripheral neuropathy (only for Part II and III).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Healthy volunteers
Young, healthy male volunteers to characterize the DBF changes upon cinnamaldehyde and capsaicin, including the reproducibility.
|
Topical application of cinnamaldehyde and capsaicin on the fingers
|
Other: Paclitaxel Patients
Group of patients after treatment with paclitaxel.
|
Topical application of cinnamaldehyde and capsaicin on the fingers
|
Other: Paclitaxel Controls
Group of healthy volunteers, matched for sex, age and BMI with the group of Paclitaxel Patients.
|
Topical application of cinnamaldehyde and capsaicin on the fingers
|
Other: Oxaliplatin Patients
Group of patients after treatment with oxaliplatin.
|
Topical application of cinnamaldehyde and capsaicin on the fingers
|
Other: Oxaliplatin Controls
Group of healthy volunteers, matched for sex, age and BMI with the group of Oxaliplatin Patients.
|
Topical application of cinnamaldehyde and capsaicin on the fingers
|
Other: Longitudinal Paclitaxel Patients
Group of patients who are treated with paclitaxel.
|
Topical application of cinnamaldehyde and capsaicin on the fingers
|
Other: Longitudinal Oxaliplatin Patients
Group of patients who are treated with oxaliplatin.
|
Topical application of cinnamaldehyde and capsaicin on the fingers
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Characterization cinnamaldehyde
Time Frame: Dermal blood flow response measured during 60 minutes post-application
|
The dermal blood flow response to topical application of cinnamaldehyde as assessed by LASCA on the fingers in healthy, male volunteers.
|
Dermal blood flow response measured during 60 minutes post-application
|
Inter-hand reproducibility cinnamaldehyde
Time Frame: Dermal blood flow response measured simultaneously on both hands during 60 minutes post-application during study visit 1
|
The within subject inter-hand reproducibility of the dermal blood flow response to topical application of cinnamaldehyde as assessed by LASCA on the fingers in healthy, male volunteers
|
Dermal blood flow response measured simultaneously on both hands during 60 minutes post-application during study visit 1
|
Inter-period reproducibility cinnamaldehyde
Time Frame: Interval of at least 5 days between both periods
|
The within subject inter-period reproducibility (i.e.
assessing changes) of the dermal blood flow response to topical application of cinnamaldehyde as assessed by LASCA on the fingers in healthy, male volunteers
|
Interval of at least 5 days between both periods
|
Characterization capsaicin
Time Frame: Dermal blood flow response measured during 60 minutes post-application
|
The dermal blood flow response to topical application of capsaicin as assessed by LASCA on the fingers in healthy, male volunteers
|
Dermal blood flow response measured during 60 minutes post-application
|
Inter-hand reproducibility capsaicin
Time Frame: Dermal blood flow response measured simultaneously on both hands during 60 minutes post-application during study visit 3
|
The within subject inter-hand reproducibility of the dermal blood flow response to topical application of capsaicin as assessed by LASCA on the fingers in healthy, male volunteers.
|
Dermal blood flow response measured simultaneously on both hands during 60 minutes post-application during study visit 3
|
Inter-period reproducibility capsaicin
Time Frame: Interval of at least 5 days between both periods
|
The within subject inter-period reproducibility (i.e.
assessing changes) of the dermal blood flow response to topical application of capsaicin as assessed by LASCA on the fingers in healthy, male volunteers.
|
Interval of at least 5 days between both periods
|
DBF patients compared to healthy volunteers
Time Frame: Dermal blood flow measured in patients who are suffering from CIPN 1 to 12 months after the last administration of paclitaxel or oxaliplatin.
|
The dermal blood flow changes upon topical application of cinnamaldehyde and capsaicin in patients suffering from chemotherapy-induced peripheral neuropathy compared to matched healthy volunteers.
|
Dermal blood flow measured in patients who are suffering from CIPN 1 to 12 months after the last administration of paclitaxel or oxaliplatin.
|
DBF in patients before, during and after chemotherapeutic treatment
Time Frame: Dermal blood flow measured prior to the first, or within 5 days after administration of paclitaxel or oxaliplatin
|
The dermal blood flow changes upon topical application of cinnamaldehyde and capsaicin in patients prior to, during and after treatment with either paclitaxel or oxaliplatin.
|
Dermal blood flow measured prior to the first, or within 5 days after administration of paclitaxel or oxaliplatin
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jan de Hoon, MD, PhD, MSc, Center for Clinical Pharmacology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Sensory System Agents
- Antineoplastic Agents
- Protective Agents
- Antineoplastic Agents, Phytogenic
- Dermatologic Agents
- Antipruritics
- Antimutagenic Agents
- Capsaicin
- Cinnamaldehyde
Other Study ID Numbers
- CCP19-3307-CIPN
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chemotherapy-induced Peripheral Neuropathy
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Leiden University Medical Center; Reinier de GraafRecruitingChemotherapy-induced Peripheral Neuropathy | CIPN - Chemotherapy-Induced Peripheral Neuropathy | Qutenza | DuloxetineNetherlands
-
Arash Asher, MDVoxxLifeRecruitingNeuropathy | Chemotherapy-induced Peripheral Neuropathy | Neuropathy;PeripheralUnited States
-
Institut Cancerologie de l'OuestGrünenthal GmbHNot yet recruitingChemotherapy-induced Peripheral Neuropathy
-
Odense University HospitalAarhus University Hospital; University of Southern Denmark; Sygehus LillebaeltRecruitingChemotherapy-induced Peripheral NeuropathyDenmark
-
WinSanTor, IncRecruitingChemotherapy-induced Peripheral NeuropathyUnited States
-
Veloxis PharmaceuticalsRecruitingChemotherapy-induced Peripheral NeuropathyUnited States, Japan
-
National University Hospital, SingaporePaxman Coolers Ltd.; The N.1 Institute for Health, National University of SingaporeRecruitingChemotherapy-induced Peripheral NeuropathySingapore
-
University of Rochester NCORP Research BaseNational Cancer Institute (NCI)RecruitingChemotherapy-Induced Peripheral NeuropathyUnited States
-
Donna Hammond, PhDActive, not recruitingChemotherapy-induced Peripheral NeuropathyUnited States
-
University of Rochester NCORP Research BaseNational Cancer Institute (NCI)CompletedEffects of Transcutaneous Electrical Nerve Stimulation on Chemotherapy-Induced Peripheral NeuropathyChemotherapy-Induced Peripheral NeuropathyUnited States
Clinical Trials on Cinnamaldehyde and capsaicin
-
Aalborg UniversityUnknownPain | Neuropathic Pain | Pruritus | Dermatology/Skin - OtherDenmark
-
Maastricht University Medical CenterTop Institute Food and NutritionCompleted
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI)TerminatedSmoking | HealthyUnited States
-
Hospital de MataróCompletedDysphagia | Oropharyngeal Dysphagia | Swallowing DisorderSpain
-
University of FloridaCompletedPain | FibromyalgiaUnited States
-
Nantes University HospitalRecruitingNeuropathic Pain | Coccyx Disorder | CoccygodyniaFrance
-
University of FloridaCompleted
-
Samyang Biopharmaceuticals CorporationCompletedPostherpetic Neuralgia | Peripheral Nerve InjuryKorea, Republic of
-
NeurogesXCompletedHIV Infections | Pain | Peripheral Nervous System Diseases
-
The University of Texas Health Science Center,...University of California, San FranciscoActive, not recruitingMigraine | Cluster Headache | Trigeminal Autonomic Cephalgia | Hemicrania Continua | Paroxysmal Hemicrania | SUNCT | Short-Lasting Unilateral Neuralgiform Headache With Conjunctival Injection and TearingUnited States